Back to search

Article

Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder Cancer

2026-01-26

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Purpose</h4> Intravesical interferon-alpha (IFNα) gene therapy has shown promise in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Ongoing work in our lab aims to further improve its treatment efficacy by identifying resistance mechanisms and deploying targeted combination treatment strategies. <h4>Experimental design</h4> We performed end-tumor RNA-seq analysis of M...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3b49586d-6ac7-50c9-89cf-67f683ee8112
DOI
10.64898/2026.01.23.701130
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder CancerDOI 10.64898/2026.01.23.701130
Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistanceSemantic proximity
Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity
Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancerSemantic proximity
The urothelial transcriptomic response to interferon gamma predicts T1 recurrence-free and basal/squamous muscle-invasive bladder cancer survival and better targeted strategies for immune checkpoint blockingSemantic proximity
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responsesSemantic proximity
A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report.Semantic proximity
Effects and mechanisms of AMIGO2 in proliferation, migration and drug resistance of bladder cancerSemantic proximity
Chemoresistance-motility signature of molecular evolution to chemotherapy in non-muscle-invasive bladder cancer and its clinical implicationsSemantic proximity
FOXA1 overexpression suppresses interferon signaling and immune response in cancerSemantic proximity
Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerSemantic proximity
Emerging therapeutic targets in bladder cancer.Semantic proximity
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.Semantic proximity
Select a neighboring publication to make it the new centre.